Bulletin
Investor Alert

press release

Oct. 12, 2021, 7:00 a.m. EDT

Protagonist Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit

NEWARK, Calif., Oct. 12, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. /zigman2/quotes/205674595/composite PTGX +5.69% ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer and Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology will participate in a fireside chat at the upcoming Jefferies Next Generation IBD Therapeutics Summit taking place virtually on October 19, 2021.

Presentation details: Date: Tuesday, October 19, 2021
Time: Available on-demand starting at 10:45 a.m. EST

A webcast of the event will be available for 90 days on the Investors section of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/ .

About Protagonist Therapeutics

Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's proprietary technology platform.

Protagonist's pipeline includes rusfertide (PTG-300), an investigational, injectable hepcidin mimetic currently in a Phase 2 proof-of-concept clinical trial for polycythemia vera (PV), a Phase 2 study in PV subjects with high hematocrit levels, and a Phase 2 study for hereditary hemochromatosis. The Company plans to initiate a single, global Phase 3 randomized, placebo-controlled trial evaluating the efficacy and safety of a once weekly, subcutaneously self-administered dose of rusfertide.

The Company is also evaluating an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide (PN-943) currently in a Phase 2 study in adults with moderate to severe active ulcerative colitis (UC). The Company is targeting ulcerative colitis as the initial indication.

The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of oral peptide IL-23 receptor antagonists. Compounds included in this agreement are PTG-200, PN-235 and PN-232. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. PN-235 and PN-232, both second-generation oral interleukin-23 receptor antagonist candidates, are currently in Phase 1 studies.

Protagonist is headquartered in Newark, California. For further information, please visit www.protagonist-inc.com .

Cision
View original content to download multimedia: https://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-jefferies-next-generation-ibd-therapeutics-summit-301397480.html

SOURCE Protagonist Therapeutics, Inc.

COMTEX_395010786/2454/2021-10-12T07:00:27

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright (C) 2021 PR Newswire. All rights reserved

/zigman2/quotes/205674595/composite
US : U.S.: Nasdaq
$ 32.69
+1.76 +5.69%
Volume: 556,169
Dec. 2, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.48 billion
Rev. per Employee
$362,380
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.